Nuvalent filed a new drug application for an experimental non-small cell lung cancer treatment with the Food and Drug Administration.
NDA based on data from global ARROS-1 Phase 1/2 clinical trial FDA assigns PDUFA target action date of September 18, 2026 CAMBRIDGE, Mass., Nov. 19, 2025 ...
Hoschton resident Joanne Cure survived stage 4 lung cancer after being given two years to live. Her treatment included ...
Dr. Andrew Ashby from Washington County Hospital & Clinics talks lung cancer screening, cold and flu season, and why rural ...
Amgen's Imdelltra received full approval from the Food and Drug Administration for use in patients with lung cancer. The biotechnology company said Wednesday Imdelltra received approval for adult ...
Bayer’s sevabertinib picks up a second-line indication for HER2-mutated disease, joining Boehringer’s zongertinib on the US ...
The FDA announced accelerated approval of sevabertinib (Hyrnuo) for HER2-positive non-small cell lung cancer (NSCLC).
The U.S. Food and Drug Administration on Wednesday said it has approved Bayer's drug for patients with a type of lung cancer ...
Some lung cancers manage to overcome a targeted drug therapy despite it showing initial success. Yale researchers have now ...
The Food and Drug Administration (FDA) granted traditional approval to Imdelltra (tarlatamab-dlle) for adult patients with ...
Early detection of lung cancer can drastically improve survival rates. Sponsored by Virginia Mason Franciscan Health.
FOX 5 Journalist Judayah Murray shares the inspiring story of Joanne Cure, a woman who developed advanced lung cancer despite ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback